Small cell carcinoma of the endometrium: A report of three cases

Üreyen, Işın; Karalök, Alper; Turan, Taner; Boran, Nurettin; Tapisiz, Omer Lutfi; Ökten, Heyecan; Köse, Mehmet; Tulunay, Gökhan

doi:10.5152/jtgga.2013.33396

Cited by 13 publications

(3 citation statements)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy to mention that 69.0% cases had advanced FIGO stages (stage III and IV) among those with neuroendocrine carcinoma of the endometrium; this rate was clearly higher than that of grade 1 endometrioid carcinoma of the endometrium (15.1%). In the past reports, it was suggested that the key factor determining the prognosis of neuroendocrine carcinoma of the endometrium was the FIGO stage [102021]. In this study, OS was significantly decreased among cases with advanced (FIGO stage III and IV) versus early (FIGO stage I and II) stages (p=0.001).…”

Section: Discussionmentioning

confidence: 47%

Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan

et al. 2019

View full text Add to dashboard Cite

ObjectiveWe conducted a retrospective, multi-institutional, collaborative study to accumulate cases of neuroendocrine carcinoma of the endometrium, to clarify its clinicopathologic features, treatment, prognosis and prognostic factors to collate findings to establish future individualized treatment regimens. To our knowledge, this is the largest case study and the first study to statistically analyze the prognosis of this disease.MethodsAt medical institutions participating in the Kansai Clinical Oncology Group/Intergroup, cases diagnosed at a central pathologic review as neuroendocrine carcinoma of the endometrium between 1995 and 2014 were enrolled. We retrospectively analyzed the clinicopathologic features, treatment, prognosis and prognostic factors of this disease.ResultsA total of 65 cases were registered from 18 medical institutions in Japan. Of these, 42 (64.6%) cases were diagnosed as neuroendocrine carcinoma of the endometrium based on the central pathological review and thus included in the study. Advanced International Federation of Gynecology and Obstetrics stages (stage III and IV) and pure type small cell neuroendocrine carcinoma cases had a significantly worse prognosis. Upon multivariate analysis, only histologic subtypes and surgery were significant prognostic factors. Pure type cases had a significantly worse prognosis compared to mixed type cases and complete surgery cases had a significantly better prognosis compared to cases with no or incomplete surgery.ConclusionOur findings suggest that complete surgery improves the prognosis of neuroendocrine carcinoma of the endometrium. Even among cases with advanced disease stages, if complete surgery is expected to be achieved, clinicians should consider curative surgery to improve the prognosis of neuroendocrine carcinoma of the endometrium.

show abstract

Section: Discussionmentioning

confidence: 47%

Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan

et al. 2019

View full text Add to dashboard Cite

show abstract

“…In this study, we compared the prognoses of SCNEC and LCNEC. Several studies have indicated that SCNEC is the most common histological subtype of endometrial NETs (1,5,6,16,(26)(27)(28). While some authors have reported worse prognosis for SCNEC than for LCNEC (8), others have reported that LCNEC tends to be more aggressive and has a worse prognosis than SCNEC (1,6,29).…”

Section: Discussionmentioning

confidence: 99%

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Zhang

Pang

2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveTo analyze clinical behavior of, optimal treatment regimens for, outcomes, and prognosis of 170 patients with neuroendocrine tumors (NETs) of the endometrium.MethodsThe Surveillance, Epidemiology, and End Results database was used to identify patients with endometrial NETs diagnosed between 2004 and 2015. Clinical features and treatment regimens were analyzed, and 5-year overall survival (OS) and cancer-specific survival (CSS) were compared among different stages and treatment regimens. Univariate and multivariate analyses were performed to identify independent prognostic factors associated with endometrial NETs. Finally, prognosis was compared between small- and large-cell neuroendocrine carcinoma (SCNEC and LCNEC, respectively) of the endometrium.ResultsThere were 20, 8, 47, and 95 patients with stage I, II, III, and IV NET, respectively. The 5-year OS rates of patients in each stage were 59.86%, 42.86%, 32.75%, and 6.04%, respectively. The 5-year CSS survival rates were 59.86%, 50.0%, 38.33%, and 6.39%, respectively. In the multivariate analysis, American Joint Committee on Cancer (AJCC) stage and treatment were associated with poor OS, while AJCC stage, nodal metastasis, and treatment were associated with poor CSS. Neither pathological type nor distant metastasis was associated with prognosis. The rate of distant metastasis was significantly higher for LCNEC than for SCNEC, while 5-year OS and CSS rates were significantly lower.ConclusionComplete surgical treatment should be selected regardless of staging for patients with endometrial NETs. For early-stage disease, individualized postoperative treatment with single chemotherapy or radiotherapy may improve OS and CSS. For advanced-stage disease, comprehensive postoperative adjuvant therapy may improve OS and CSS.

show abstract

“…The reported five-year OS has ranged from 32%−50% for early stages and 0%−10% for advanced stage disease (3,5,11). In general, combination therapy including surgery, chemotherapy, and radiation therapy have been recommended, though each study has included heterogeneous stages of cancer (4,10,11,14,18,19). A recent analysis of 487 patients in the Surveillance, Epidemiology, and End Results (SEER) database is the largest review after this study to focus on small cell cancer of the cervix (20).…”

Section: Discussionmentioning

confidence: 99%

Brachytherapy and survival in small cell cancer of the cervix and uterus

et al. 2019

View full text Add to dashboard Cite

Background: Small cell cancer involving the cervix and uterus is considered the same rare disease, but management is controversial and disparate. Patterns of care and outcomes in the United States are unclear.Methods: Clinical data from patients with small cell cancer of the cervix and uterus were abstracted from the National Cancer Database (NCDB) from 2004-2014. Patients with missing clinical stage, incomplete follow up, or receiving treatment >90 days from diagnosis were excluded.Results: There were 621 cervical and 95 uterine cancer patients treated from 2004-2014. Compared to patients with a cervix primary site, patients with a uterine primary site were older (median age 64 years vs. 47 years), more likely to present with distant metastatic disease (47% vs. 33%), less likely to receive any pelvic radiation (31% vs. 64%), less likely to receive brachytherapy (3% vs. 27%), more likely to have at least a total hysterectomy (58% vs 28%), and less likely to receive chemotherapy (74% vs. 88%), all p<0.05.). Brachytherapy was associated with improved overall survival (OS) for patients with locally advanced cervical small cell carcinoma (II-IVA, p=0.03), but only 38% of patients with stage II-IVA disease received brachytherapy. For the uterine site, hysterectomy (p=0.001) and external irradiation (p=0.03) were associated with improved OS in unadjusted Kaplan-Meier analysis, but only chemotherapy and stage were significantly associated with higher OS in multivariable analysis.Conclusions: Brachytherapy may improve OS for stage II-IVA small cell cancer of the cervix, but appears underutilized. Brachytherapy was not commonly delivered for uterine primaries.

show abstract

Small cell carcinoma of the endometrium: A report of three cases

Cited by 13 publications

References 9 publications

Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan

Clinicopathologic features, treatment, prognosis and prognostic factors of neuroendocrine carcinoma of the endometrium: a retrospective analysis of 42 cases from the Kansai Clinical Oncology Group/Intergroup study in Japan

Primary Neuroendocrine Tumors of the Endometrium: Management and Outcomes

Brachytherapy and survival in small cell cancer of the cervix and uterus

Contact Info

Product

Resources

About